Show simple item record

dc.contributor.authorKiltie, Anne E
dc.contributor.authorCollins, Conor D
dc.contributor.authorGattamaneni, Rao
dc.contributor.authorShalet, Stephen M
dc.date.accessioned2010-03-23T15:04:52Z
dc.date.available2010-03-23T15:04:52Z
dc.date.issued1997-07
dc.identifier.citationRelapse of intracranial germinoma 23 years postirradiation in a patient given growth hormone replacement. 1997, 29 (1):41-4 Med. Pediatr. Oncol.en
dc.identifier.issn0098-1532
dc.identifier.pmid9142205
dc.identifier.doi10.1002/(SICI)1096-911X(199707)29:1<41::AID-MPO8>3.0.CO;2-S
dc.identifier.urihttp://hdl.handle.net/10541/94690
dc.description.abstractThere is no clear evidence that growth hormone replacement therapy for treatment-related growth hormone deficiency in patients with childhood intracranial malignancies has a role in tumour relapse or second malignancy. A 16-year-old girl with an intracranial germinoma was treated with local radiotherapy and subsequently received growth hormone replacement therapy as an adult. Three years after starting growth hormone therapy, 23 years after her radiotherapy treatment, the patient's tumour recurred. Surveillance requirements for patients receiving growth hormone in this setting are discussed.
dc.language.isoenen
dc.subjectCancer Recurrenceen
dc.subjectBrain Canceren
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBrain Neoplasms
dc.subject.meshFatal Outcome
dc.subject.meshFemale
dc.subject.meshGerminoma
dc.subject.meshGrowth Hormone
dc.subject.meshHumans
dc.subject.meshHypopituitarism
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshRadiotherapy, Adjuvant
dc.subject.meshSella Turcica
dc.titleRelapse of intracranial germinoma 23 years postirradiation in a patient given growth hormone replacement.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.en
dc.identifier.journalMedical and Pediatric Oncologyen
html.description.abstractThere is no clear evidence that growth hormone replacement therapy for treatment-related growth hormone deficiency in patients with childhood intracranial malignancies has a role in tumour relapse or second malignancy. A 16-year-old girl with an intracranial germinoma was treated with local radiotherapy and subsequently received growth hormone replacement therapy as an adult. Three years after starting growth hormone therapy, 23 years after her radiotherapy treatment, the patient's tumour recurred. Surveillance requirements for patients receiving growth hormone in this setting are discussed.


This item appears in the following Collection(s)

Show simple item record